For a Sixth Time, Priority OnDemand Makes the Inc. 5000 of Fastest Growing Private Companies
August 13, 2024 09:05 ET
|
Priority OnDemand
New York, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Inc. revealed today that Priority OnDemand ranks No. 4573 on the 2024 Inc. 5000, its annual list of the fastest-growing private companies in America. The...
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
August 13, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
RTLS for Healthcare Market Share Will Reach Over USD 17.16 Billion by 2034, at 19.8% CAGR: Prophecy Market Insights
August 13, 2024 08:24 ET
|
PMI
Covina, Aug. 13, 2024 (GLOBE NEWSWIRE) -- According to Prophecy Market Insights, the global RTLS for healthcare market size and share is projected to grow from USD 3.3 Billion in 2024 and is...
NGS-Based RNA-Sequencing Market Size Worth Over USD 11.1 Billion by 2034 | CAGR of 18.10%: Prophecy Market Insights
August 13, 2024 08:06 ET
|
PMI
Covina, Aug. 13, 2024 (GLOBE NEWSWIRE) -- According to Prophecy Market Insights, the global NGS-based RNA-sequencing market size and share is projected to grow from USD 2.1 Billion in 2024 and is...
Noema Pharma Announces Completion of Enrollment for GALENE Phase 2B Trial Evaluating NOE-101, a First-in-Class mGluR5 NAM, for Seizure Control in Tuberous Sclerosis Complex
August 13, 2024 08:00 ET
|
Noema Pharma AG
-- Top-line results from Phase 2B study expected in first quarter of 2025 -- BASEL, Switzerland, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Noema Pharma AG, a clinical-stage biotech company targeting...
Cue Biopharma to Host Business Update Call and Webcast
August 13, 2024 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis
August 13, 2024 08:00 ET
|
Biomed Valley Discoveries, Inc.
Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
August 13, 2024 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
August 13, 2024 08:00 ET
|
Daré Bioscience, Inc.
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in...
(BaaS) Biometrics As a Service in Healthcare Market Size to Hit USD 3666.41 Million Mark by 2034, at 17.2% CAGR: Prophecy Market Insights
August 13, 2024 07:36 ET
|
PMI
Covina, Aug. 13, 2024 (GLOBE NEWSWIRE) -- According to Prophecy Market Insights, the global biometrics as a service in healthcare market size and share is projected to grow from USD 862.66 Million...